Compare AbCellera Biologics Inc (ABCL) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Gilead Sciences, Inc. — how do they compare? AbCellera Biologics Inc trades at $7.18 (market cap $2.35B), while Gilead Sciences, Inc. trades at $135.39 (market cap $169.30B). The key difference: Gilead Sciences, Inc. is far larger — about 72× AbCellera Biologics Inc's market cap, and Gilead Sciences, Inc. pays a 2.41% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | GILD | |
|---|---|---|
Market Cap | $2.35B | $169.30B |
Sector | Health | Health |
52-Week High | $8.12 | $155.80 |
52-Week Low | $2.78 | $108.22 |
Enterprise Value | $1.99B | $183.83B |
Dividend Yield | — | 2.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Gilead Sciences (GILD) trades at $136.36, up 3.88% today and 25.2% over the past year, showing strong momentum. The stock exhibits bullish technical signals with support at $128 and resistance at $136. Fundamentally, GILD maintains robust profitability with a 30.99% net margin and has beaten earnings estimates for three consecutive quarters. Recent FDA and EC approvals for Trodelvy's expanded use in metastatic triple-negative breast cancer provide significant growth catalysts.
GILD presents a compelling investment case with strong analyst support (65.5% buy ratings) and a $156.14 consensus price target offering 14.5% upside. Key risks include generic competition for dolutegravir and execution challenges in oncology growth. The company's solid cash flow generation and expanding product portfolio support continued shareholder value creation despite recent negative net cash flow trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
